ABOUT US
About HLB
Greeting
History
Location
GROUP
Pharma·Bio
Ship ·Plant ·Energy
Life · Health · Leisure
Finance
BUSINESS
Pharma·Bio
cytotoxic antineoplastic drug
targeted therapy
immunotherapy
Healthcare
Special ship
ESG
EHS
EHS경영
친환경 제품 및 서비스
인증 및 수상
CSR
Human resources
인재육성 제도
복리후생
직원안전 및 보건
핵심고용지표
Governance
주주
이사회
정관
기타
Initiative
ESG Report
IR
Stock Index
Official Notice
PR
Press
Library
CAREERS
Recruiting
ENG
Korean
English
home
Title + Content
Title+Content
Title
Content
Search
Number
Title
Author
Date
148
HLB increases stake in HLB Therapeutics to 6.25%
admin
2024.03.20
147
HLB Pharmaceutical secures domestic rights to riboceranib+camrelizumab combo
admin
2024.03.08
146
US FDA approval imminent… HLB affiliates are all strong
admin
2024.02.29
145
FDA Approved 48.65% More Novel Drugs in 2023. HLB Says 'Definitely Achieve It This Year'
admin
2024.01.08
144
Rivoceranib Combination Shows Efficacy in Neoadjuvant Chemotherapy for GC Patients
admin
2024.01.05
143
HLB Panagene Receives Export Licenses for Two Cancer-Related Mutation Test Kits
admin
2023.12.27
142
HLB's US Subsidiary Signs Licensing Consultancy Agreement with European Pharma for Liver Cancer Drug
admin
2023.12.27
141
HLB's shareholders approve plan to move to main bourse from KOSDAQ
admin
2023.12.22
140
HLB Becomes a Foreign Investor Favorite After Short-Selling Ban
admin
2023.12.14
139
[ESMO 2023] ‘HLB will apply for European authorization for rivoceranib this year’
admin
2023.10.23
1
2
3
4
5
6
7
8
9
10
>
>>